https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
1 (95% confidence interval, CI 1.7-24.6) mg/cm (+1.6%, 95% CI 0.3%, 2.8%) after a median time of 102 weeks (IQR 84-11. As regards LS BMD, patients with osteopenia/osteoporosis at study entry experienced a high increase from baseline (20.6, 95% CI 3.1, 38.1 mg/cm ), as well as experienced subjects (16.9, 95% CI 4.7, 29.2 mg/cm ) and those on vitamin D supplementation (26.8, 95% CI 7.7, 45.9 mg/cm ). Dolutegravir-containing regimens could reduce the negative impact of antiretroviral therapy on bone, especially in patients wi
Like
Comment
Share
